Medexus Pharmaceuticals Inc. (V:MDP)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Apr 02, 2024 07:30 am ET

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.

Mar 26, 2024 07:53 am ET

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group

Feb 07, 2024 05:58 pm ET

Medexus Announces Fiscal Q3 2024 Results

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2023 (the company's fiscal Q3 2024). All dollar amounts in this news release are in United States dollars unless specified otherwise.

Jan 30, 2024 07:00 am ET

Medexus Schedules Third Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on February 7, 2024.

Jan 08, 2024 07:00 am ET

Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to treat fungal nail infections.

Nov 08, 2023 05:30 pm ET

Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 8, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2023 (the company's fiscal Q2 2024). All dollar amounts in this news release are in United States dollars unless specified otherwise.

Nov 01, 2023 07:00 am ET

Medexus Schedules Second Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, 2023 to discuss Medexus's results for its second fiscal quarter ended September 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on November 8, 2023.

Oct 17, 2023 09:15 am ET

Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed bought-deal public offering (Offering) of units (Units), Medexus has issued an additional 508,484 Units at a price of C$2.95 per Unit for an additional C$1.5 million in gross proceeds following exercise in full by Research Capital Corporation (Underwriter) of the Underwriter's over-allotment option pursuant to the underwriting agreement dated September 11, 2023 between Medexus and the Underwriter relating to the Offering.

Oct 16, 2023 07:00 am ET

Medexus Fully Repays Convertible Debentures In Cash At Maturity

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately US$37.5 million) to Computershare Trust Company of Canada as trustee for holders of Medexus's 6% unsecured convertible debentures due October 16, 2023 (TSX: MDP.DB). Under the terms of the indenture governing the convertible debentures, each holder will be entitled to receive from the trustee a cash payment of approximately C$1,282.71 per C$1,000 principal amount of convertible debentures, including interest of approximately C$32.71 per C$1,000 principal amount.

Oct 06, 2023 09:43 am ET

Medexus Announces Closing of C$10 Million Bought-Deal Public Offering

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900 units (Units) at a price of C$2.95 per Unit for aggregate gross proceeds to Medexus of C$10,000,205 (Offering). The net proceeds from the Offering, after deducting underwriting discounts and commissions and offering expenses, will be used for working capital and general corporate purposes, which may include funding Medexus's ongoing business development activities and initiatives.

Sep 28, 2023 07:34 pm ET

Medexus and medac Agree to Amend US Treosulfan Agreement

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment to its February 2021 exclusive license agreement with medac GmbH relating to commercialization of treosulfan in the United States.

Sep 21, 2023 05:00 pm ET

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

All director nominees reelected and all other company proposals approved by shareholders

Sep 05, 2023 06:41 pm ET

Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units

Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX: MDP) (OTCQX: MEDXF), is pleased to announce that it has entered into an agreement with Research Capital Corporation, as sole bookrunner and sole underwriter (the “Underwriter”),...

Sep 05, 2023 07:30 am ET

Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility

Medexus expects net proceeds, together with projected cash on hand, to fully satisfy convertible debentures in cash at maturity in October 2023

Aug 17, 2023 05:30 pm ET

Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced the presentation of data from a Phase 3/4 study that evaluated the pharmacokinetics (PK), safety, and efficacy of IXINITY, an intravenous recombinant factor IX therapeutic, as a prophylactic treatment in previously treated pediatric patients under 12 years of age with severe or moderately severe hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood.

Aug 09, 2023 05:30 pm ET

Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2023 (the company's fiscal Q1 2024). All dollar amounts in this news release are in United States dollars unless specified otherwise.

Aug 04, 2023 07:00 am ET

Medexus to Participate in Fireside Chat at SHARE Series Event

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time.

Aug 02, 2023 07:00 am ET

Medexus Schedules First Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 10, 2023 to discuss Medexus's results for its first fiscal quarter ended June 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on August 9, 2023.

Jul 12, 2023 05:30 pm ET

Medexus Announces Preliminary Revenue for Fiscal Q1 2024

Preliminary estimates indicate revenue is expected to exceed US$31 million for fiscal quarter ended June 30, 2023

Jun 21, 2023 05:40 pm ET

Medexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023

Management to Host Conference Call at 8:00 Am Eastern Time on Thursday, June 22, 2023

Jun 15, 2023 07:25 am ET

FDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients

Expanded indication would cover patients 12 years of age or younger, a population that comprises approximately one in three patients treated for hemophilia B in the United States

Jun 14, 2023 05:30 pm ET

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 14, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 22, 2023 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on June 21, 2023.

Jun 13, 2023 07:25 am ET

Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023

Princess Margaret Cancer Center's retrospective analysis found a 30% improvement (83.2% vs 53.2%) in one-year overall survival for patients treated with treosulfan, among other positive findings

Jun 01, 2023 05:30 pm ET

Medexus to Participate in the LD Micro Invitational XIII

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the LD Micro Invitational XIII from June 6-8 2023.

May 10, 2023 05:30 pm ET

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible Debentures

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 10, 2023) - Medexus Pharmaceuticals (TSX: MDP) (TSX: MDP.DB) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its 6% unsecured convertible debentures due 2023 (TSX: MDP.DB). Under the NCIB, Medexus may purchase for cancellation up to C$4,132,100 principal amount of convertible debentures, representing approximately 10% of the public float as defined under TSX rules. As of May 1, 2023, C$41,546,000 principal amount of convertible debentures were outstanding.

May 09, 2023 06:21 pm ET

Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma

ISPOR 2023 Presentation Shows 33% Lowered Costs with Gleolan Compared to Conventional White Light Surgery

Apr 18, 2023 05:30 pm ET

Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference from April 25 to 26, 2023. Event: 2023 Bloom Burton & Co....

Apr 11, 2023 07:25 am ET

Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update

Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter and full fiscal year ended March 31, 2023, and, in addition, is providing an additional business update to...

Mar 22, 2023 07:20 am ET

Medexus Announces New License Deal for Topical Terbinafine

Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that the company has secured Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group company focused on medical...

Mar 08, 2023 05:00 pm ET

Medexus Announces US$58.5 million in New Credit Facilities

Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO. The credit agreement provides for a US$35 million term loan facility and a US$3.5 million revolving loan facility...

Mar 06, 2023 08:00 am ET

Medexus to Participate in 35th Annual Roth Conference

Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023. Event: 35th Annual Roth ConferenceDate: March 12-14, 2023Location:...

Feb 08, 2023 05:00 pm ET

Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s third fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023). All dollar...

Feb 06, 2023 05:00 pm ET

Medexus Welcomes Two New Board Members

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of...

Feb 01, 2023 05:00 pm ET

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrrolate oral solution...

Jan 31, 2023 05:00 pm ET

Medexus Schedules Third Fiscal Quarter 2023 Conference Call

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quarter ended December 31, 2022. Medexus expects to...

Jan 12, 2023 07:30 am ET

Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023) and provide additional business...

Nov 08, 2022 05:30 pm ET

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s second fiscal quarter ended September 30, 2022. All dollar amounts in this press...

Nov 02, 2022 08:00 am ET

Medexus Schedules Second Quarter 2023 Conference Call

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, November 9, 2022 to discuss Medexus’s results for its second quarter ended September 30, 2022. Medexus expects to file...

Oct 06, 2022 07:30 am ET

Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended September 30, 2022 (the company’s fiscal Q2 2023). All dollar amounts in this...

Sep 29, 2022 05:05 pm ET

Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company’s revolving credit facility with a syndicate of lenders agented by MidCap Funding IV Trust (MidCap). Among other things, the amendment...

Sep 19, 2022 08:00 am ET

Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update

On Friday, September 16, Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus’s commercialization rights to treosulfan, that the U.S. Food and Drug Administration (FDA) has delivered to medac a...

Sep 15, 2022 05:05 pm ET

Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus’s management information circular dated August 5, 2022 as directors...

Aug 08, 2022 05:00 pm ET

Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s first fiscal quarter ended June 30, 2022. All dollar amounts in this press release are...

Aug 02, 2022 05:00 pm ET

Medexus Schedules First Quarter 2023 Conference Call

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022 to discuss Medexus’s results for its first quarter ended June 30, 2022. Medexus expects to file its...

Jul 25, 2022 07:00 am ET

Treosulfan NDA Resubmitted to FDA

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for treosulfan (NDA) with the U.S. Food and Drug Administration...

Jun 22, 2022 05:50 pm ET

Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March 31, 2022. All dollar amounts in this...

Jun 14, 2022 04:30 pm ET

Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022 to discuss Medexus’s results for its fourth quarter and fiscal year ended March 31, 2022. Medexus expects...

Jun 06, 2022 08:30 am ET

Treosulfan Pivotal Study Results Published

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that the American Journal of Hematology has accepted for publication the final study results and analysis of the pivotal phase 3 clinical trial of treosulfan conducted by...

May 26, 2022 11:00 am ET

Toronto Stock Exchange, Medexus Pharmaceuticals, The View From The C-Suite

TORONTO, May 26, 2022 /CNW/ - Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX: MDP) shares his Company's story in an interview with TMX Group.

May 24, 2022 05:05 pm ET

Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received acknowledgement of receipt from the U.S. Food and Drug Administration (FDA) of the New Drug Application...

Apr 22, 2022 08:30 am ET

Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for Treosulfan (NDA) with the U.S. Food and Drug Administration...

Apr 19, 2022 04:20 pm ET

Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference from May 2 to 3, 2022. The conference brings together U.S., Canadian, and international investors interested in...

Mar 09, 2022 08:00 am ET

Medexus to Participate in the 34th Annual Roth Conference

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be participating in the 34th Annual Roth Conference from March 13 to 15, 2022. Event: 34th Annual Roth Conference Date: March...

Mar 01, 2022 07:15 am ET

Medexus Pharmaceuticals Announces Deal for Gleolan in the United States

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that its U.S. subsidiary, Medexus Pharma (Medexus US), has acquired the exclusive right to commercialize Gleolan in the United States from NX Development Corp....

Feb 14, 2022 08:00 am ET

Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange (TSX) has accepted Medexus’s notice of intention to make a normal course issuer bid (NCIB). Under the NCIB, Medexus may purchase for...

Feb 09, 2022 06:30 pm ET

Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended December 31, 2021. All dollar amounts below are in United...

Feb 01, 2022 04:15 pm ET

Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be presenting at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference being held virtually from Feb...

Jan 31, 2022 08:00 am ET

Medexus Schedules Third Quarter Fiscal 2022 Conference Call

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, February 10th, 2022, to discuss the Company’s financial results for the...

Jan 28, 2022 10:07 am ET

36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.

Jan 07, 2022 09:00 am ET

Medexus to Present at the H.C. Wainwright BioConnect 2022 Conference

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C....

Dec 07, 2021 04:30 pm ET

Sidoti December Micro Cap Virtual Conference

Presentation Times Released for 75+ Presenting Companies

Dec 02, 2021 04:15 pm ET

Medexus to Participate in Two Upcoming Virtual Investor Conferences

Dec 02, 2021 08:08 am ET

Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced that medac clarified with FDA details with regard to the projected NDA resubmission of treosulfan, an alkylating agent licensed...

Nov 10, 2021 05:00 pm ET

Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended September 30, 2021. All dollar amounts below are in United...

Nov 10, 2021 08:30 am ET

Medexus to Present at the Q4 Investor Summit on November 17th

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021. Ken...

Nov 08, 2021 08:30 am ET

Medexus Pharmaceuticals Announces Appointment of Internal Counsel

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed Ian C Wildgoose Brown as the Company’s general counsel and corporate secretary. In this role, Mr. Wildgoose Brown will work...

Nov 04, 2021 08:30 am ET

Medexus Schedules Second Quarter Fiscal 2022 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, November 11, 2021 to discuss the Company’s financial results for the...

Nov 01, 2021 09:27 am ET

Medexus Pharmaceuticals Announces Type A Meeting with FDA Granted for Treosulfan

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type A meeting to medac for treosulfan, a bifunctional...

Oct 26, 2021 08:30 am ET

Medexus to Present at the Benzinga Global Small Cap Conference on October 28, 2021

Sep 21, 2021 06:09 pm ET

Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it has initiated its first commercial shipment of Trecondyv® (treosulfan) in Canada, following the June 28th, 2021 Notice of Compliance by...

Sep 16, 2021 04:30 pm ET

Medexus Holds Annual and Special Meeting of Shareholders and Announces Election of Board of Directors

Medexus Pharmaceuticals Inc. (the “Company”) (TSX: MDP) (OTCQX: MEDXF) today held its annual and special meeting of shareholders virtually. At the meeting, all of the nominees listed in the Company’s management information circular dated August 6,...

Sep 02, 2021 08:30 am ET

Medexus Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C....

Aug 16, 2021 05:30 pm ET

Medexus Pharmaceuticals Reports Financial and Operational Results for First Quarter Fiscal 2022

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended June 30, 2021. All dollar amounts below are in United States...

Aug 12, 2021 07:30 am ET

Medexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that is has completed enrollment in its Phase 4 Clinical Trial of IXINITY®, targeting label expansion for pediatric hemophilia B patients. The...

Aug 10, 2021 08:30 am ET

Medexus Schedules First Quarter Fiscal 2022 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, August 17, 2021 to discuss the Company’s financial results for the...

Aug 09, 2021 04:15 pm ET

Medexus to Present at Canaccord Genuity’s 41st Annual Growth Conference

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it will be presenting at the Canaccord Genuity 41st Annual Growth Conference being held virtually from August 10th to 12th, 2021. Canaccord...

Aug 04, 2021 10:58 am ET

Medexus Schedules Webinar to Discuss FDA Complete Response Letter for Treosulfan

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has scheduled a webinar on Thursday, August 5, 2021 at 10:00 a.m. Eastern Time to discuss the Complete Response Letter (CRL) that the...

Aug 03, 2021 07:45 am ET

Complete Response Letter Received from FDA for Treosulfan

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced today that medac, Medexus’ licensor for treosulfan, has received a Complete Response Letter (CRL) from the Food and Drug...

Jul 19, 2021 07:40 am ET

Medexus Appoints New Chief Financial Officer

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is...

Jul 12, 2021 09:29 am ET

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (“medac”) to commercialize treosulfan, a bifunctional...

Jul 07, 2021 11:00 am ET

Medexus Virtually Opens The Market

TORONTO, July 7, 2021 /CNW/ - Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals Inc., ("Medexus" or the "Company") (TSX: MDP), and his team joined Daniel Lubienietzky, Manager, Life Sciences, TMX Group, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.

Jun 28, 2021 04:30 pm ET

Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has received a Notice of Compliance (“NOC”) from Health Canada to commercialize treosulfan, developed by medac GmbH, in Canada, following...

Jun 16, 2021 05:00 pm ET

Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2021. As greater than 75% of the Company’s revenue is now...

Jun 15, 2021 04:05 pm ET

Medexus Announces Graduation to the Toronto Stock Exchange

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final approval for listing of the Company’s common shares (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”). In...

Jun 14, 2021 08:30 am ET

Medexus to Present at Raymond James Human Health Innovation Conference

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Raymond James Human Health Innovation Conference on June 21st, 2021. Ken d’Entremont, Chief...

Jun 11, 2021 08:30 am ET

Medexus Schedules Fiscal Year 2021 Conference Call

, June 11, 2021 - Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, June 17, 2021 to discuss the...

Jun 10, 2021 08:30 am ET

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating...

Jun 09, 2021 08:30 am ET

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone Hexacetonide Injectable Suspension, USP (20 mg/ml) (TH) in the...

Jun 01, 2021 08:30 am ET

Medexus to Present at The LD Micro Virtual Invitational XI on June 8th

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021. Ken d’Entremont, Chief...

May 27, 2021 05:00 pm ET

Medexus Announces Amendments to its Credit Agreements

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has entered into certain amendments (collectively, the “Amendments”) to its existing credit agreements with a syndicate of...

May 18, 2021 05:30 pm ET

Sidoti Microcap Virtual Conference

May 19 - 20, 2021

May 12, 2021 08:30 am ET

Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Sidoti & Company Virtual Microcap Conference being held on May 19th - May 20th, 2021. Ken...

Apr 12, 2021 08:30 am ET

Medexus Announces Conference Participation for April 2021

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will be participating in the Bloom Burton & Co. Healthcare Investor...

Mar 31, 2021 05:05 pm ET

Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company’s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted...

Mar 08, 2021 08:30 am ET

Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1...

Mar 01, 2021 05:00 pm ET

Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced its financial and operating results for the three and nine months ended December 31, 2020. All dollar amounts below are in...

Feb 25, 2021 09:00 am ET

Medexus Announces Expanded Availability of Gleolan® in Canada

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has initiated the commercial launch of Gleolan® in Canada, which had previously only been distributed under the Health...

Feb 24, 2021 09:00 am ET

Medexus Schedules Third Quarter Fiscal 2021 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial...

Feb 23, 2021 08:51 am ET

Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) announced today that it has closed its previously announced bought deal public offering of 4,581,689 units (the “Units”) at a price of $7.10 per Unit for total...

Feb 16, 2021 04:43 pm ET

Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February...

Feb 03, 2021 10:09 am ET

Medexus Announces Upsize to Previously Announced Bought Deal Public Offering

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) is pleased to announce that, due to strong demand, it has agreed with Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf...

Feb 03, 2021 09:44 am ET

IIROC Trading Resumption - MDP

VANCOUVER, BC, Feb. 3, 2021 /CNW/ - Trading resumes in:

Feb 02, 2021 03:03 pm ET

Medexus Announces $20 Million Bought Deal Public Offering of Units

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) is pleased to announce that it has entered into an agreement with Raymond James Ltd. and Stifel GMP as co-lead underwriters and joint bookrunners, on behalf of a...

Feb 02, 2021 02:21 pm ET

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States

Medexus Pharmaceuticals Inc. (“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“Medexus Pharma” and together with Medexus, the...

Feb 02, 2021 02:04 pm ET

IIROC Trading Resumption - MDP

VANCOUVER, BC, Feb. 2, 2021 /CNW/ - Trading resumes in:

Feb 02, 2021 01:59 pm ET

IIROC Trading Halt - MDP

VANCOUVER, BC, Feb. 2, 2021 /CNW/ - The following issues have been halted by IIROC:

Feb 02, 2021 01:16 pm ET

IIROC Trading Halt - MDP

VANCOUVER, BC, Feb. 2, 2021 /CNW/ - The following issues have been halted by IIROC:

Jan 25, 2021 08:30 am ET

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has renewed and expanded its distribution agreement for NYDA®, a market leading treatment for head lice, through...

Jan 21, 2021 08:30 am ET

Medexus Submits Application to List on the Nasdaq

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “Nasdaq”). Ken d’Entremont, Chief Executive...

Jan 06, 2021 05:00 pm ET

Medexus Engages Independent Trading Group for Market Making Services

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has engaged Independent Trading Group (ITG), Inc. (“ITG”) to provide market-making services to the Company in accordance...

Dec 29, 2020 09:30 am ET

TMX Group, Medexus, C-Suite at The Open

TORONTO, Dec. 29, 2020 /CNW/ - Ken d'Entremont, CEO, Medexus Pharmaceuticals Inc. (TSXV: MDP), shares his company's story in an interview with TMX Group.

Dec 21, 2020 05:30 pm ET

Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that the board of directors of the Company (the “Board”) has formally granted (the “Annual Grants”) restricted share units...

Dec 21, 2020 08:52 am ET

Medexus (MDP.V) expands specialty pharmaceuticals portfolio

By Global Stocks News

Dec 21, 2020 08:52 am ET

Medexus (MDP.V) expands specialty pharmaceuticals portfolio

By Global Stocks News

Dec 18, 2020 08:30 am ET

Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with Ethypharm

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce it has entered into an exclusive license agreement with Ethypharm (“Ethypharm”) to register and commercialize...

Dec 08, 2020 08:30 am ET

Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15th at 8:00 a.m. PST / 11:00 a.m. EST....

Dec 07, 2020 07:35 am ET

Innovation Investor Conference Presentations Now Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Dec 07, 2020 07:35 am ET

Innovation Investor Conference Presentations Now Available for On-Demand Viewing

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the Innovation Virtual lnvestor Conference are now available for on-demand viewing.

Dec 02, 2020 07:30 am ET

Medexus to Webcast Live at VirtualInvestorConferences.com December 3rd

TORONTO and CHICAGO and MONTREAL, Dec. 2, 2020 /PRNewswire/ -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV: MDP, OTCQX: MEDXF), today announced that Ken d'Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer of Medexus, will present live at VirtualInvestorConferences.com on December 3rd.

Nov 30, 2020 08:38 am ET

Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd

Company executives will share vision and answer audience questions at VirtualInvestorConferences.com

Nov 30, 2020 08:28 am ET

Live Innovation Investor Conference & Webinar: Public Company Presentations December 3rd

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Innovation lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, December 3rd with the first live webcast at 9:00 AM ET.

Nov 16, 2020 05:15 pm ET

Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 2020

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced its financial and operating results for the three and six months ended September 30, 2020. All dollar amounts below are in Canadian...

Nov 16, 2020 08:00 am ET

Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) today announced it has reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients...

Nov 09, 2020 08:30 am ET

Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2021 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, November 17, 2020 to discuss the Company’s financial...

Oct 30, 2020 12:30 pm ET

Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has entered into a consulting agreement (the “Consulting Agreement”) with Westmount Capital (“Westmount”) to provide...

Oct 08, 2020 03:30 pm ET

The MicroCap Rodeo Best Ideas Bowl 2020; October 13-16, 2020

NEW YORK, NY / ACCESSWIRE / October 8, 2020 / The MicroCap Rodeo continues this year with its first virtual event set for October 13-16, 2020. This year' "Best Ideas" conference focuses solely on 25 public companies recommended by institutional investors and qualified individual investors. The event will feature 2 days of company presentations followed by 2 days of pre-scheduled 1-1's.

Sep 25, 2020 08:30 am ET

Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s...

Sep 18, 2020 10:38 am ET

Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) is pleased to announce that it has entered into a consulting agreement (the “Consulting Agreement”) with Adelaide Capital (“Adelaide”) to provide investor...

Sep 10, 2020 09:20 am ET

Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) today announces that on September 9, 2020, it received a Notice of Compliance from Health Canada granting approval for the marketing of Gleolan® in Canada....

Aug 31, 2020 05:00 pm ET

LD Micro - 360 Companies - Set to Present this Week

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Aug 25, 2020 09:30 am ET

Medexus to Present at The LD 500 Virtual Conference on September 1st

MONTREAL, QC / ACCESSWIRE / August 25, 2020 / Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP) (OTCQX:MEDXF) today announced that it will be presenting at the LD 500 Investor conference being held virtually on September 1-4, 2020.

Aug 24, 2020 07:57 pm ET

Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that due to public health restrictions related to the COVID-19 pandemic, its annual general meeting (the “Meeting”) will be held virtually by live...

Aug 24, 2020 08:00 am ET

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medications (Basic Plan and Institutions)

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion as a general benefit (open listing) on...

Aug 21, 2020 11:36 am ET

Medexus Announces New U.S. Ticker “MEDXF” on the OTCQX

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF; PDDPF) today announces that it has begun trading on the OTCQX® Best Market under the new ticker “MEDXF,” effective August 20, 2020. Medexus Pharmaceuticals Inc was...

Aug 11, 2020 05:19 pm ET

Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of Fiscal 2021

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today provided a business update and announced its financial and operating results for the three-month period ended June 30, 2020. All dollar amounts below are in...

Aug 11, 2020 08:30 am ET

Medexus Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it will be presenting at the Canaccord Genuity 40th Annual Growth Conference being held virtually on August 11-13, 2020. Ken d’Entremont,...

Aug 05, 2020 09:00 am ET

LD Micro - Announces Preliminary List of Presenters for the LD 500

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Aug 05, 2020 08:30 am ET

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2021 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, August 12, 2020 to discuss the Company’s financial results for the...

Aug 04, 2020 04:30 pm ET

OTC Markets Group Welcomes Medexus Pharmaceuticals Inc. to OTCQX

NEW YORK, Aug. 4, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Medexus Pharmaceuticals Inc. (TSX-V: MDP; OTCQX: PDDPF), a commercial-stage specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market. Medexus Pharmaceuticals Inc upgraded to OTCQX from the OTCQB® Venture Market.

Jul 09, 2020 08:30 am ET

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Public Drug Plan Formularies

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on the Alberta Drug Benefit List (ADBL),...

Jun 22, 2020 05:15 pm ET

Medexus Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fourth quarter and fiscal year ended March 31, 2020. All dollar amounts...

Jun 17, 2020 09:15 am ET

Medexus Pharmaceuticals Schedules Fiscal Year 2020 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, June 23, 2020 to discuss the Company’s financial results for the fiscal...

Jun 03, 2020 09:00 am ET

Medexus to Present at the Virtual Summer Summit on June 10th

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that it will be presenting at the 2020 Virtual Summer Summit being held on June 9th-12th. Ken d’Entremont, CEO and Roland Boivin, CFO are...

Jun 03, 2020 09:00 am ET

47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9th-12th, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations.

May 22, 2020 08:51 am ET

Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update on its business in light of the recent transformative acquisition of the commercial hematology asset, IXINITY®, the resulting...

May 07, 2020 05:00 pm ET

Medexus Announces US$20 Million Asset-Based Credit Facility and Repays US$10 Million of its Term Loan

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that the Company has entered into a definitive credit agreement with a syndicate of lenders agented by MidCap Financial Trust (“MidCap Financial”)...

Apr 08, 2020 08:30 am ET

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH) in...

Mar 23, 2020 01:24 pm ET

Medexus to Present at the Spring Investor Summit on March 25th

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that it will be presenting at the 2020 Spring Investor Summit being held on March 25th-26th, featuring over 500 registered executives and...

Mar 23, 2020 08:30 am ET

Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update to its shareholders reaffirming the strength of its business and outlining the measures it has taken in light of the COVID-19 healthcare...

Feb 28, 2020 08:59 am ET

Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the Company, through its US-based subsidiary, acquired Aptevo BioTherapeutics LLC, a Delaware limited liability company owning the worldwide...

Feb 18, 2020 06:52 pm ET

Medexus Pharmaceuticals Reports Revenue of $16.2 Million for the Third Quarter of Fiscal 2020

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the three- and nine- month periods ended December 31, 2019. All dollar...

Feb 12, 2020 08:30 am ET

Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2020 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, February 19, 2020 to discuss the Company’s financial results for the...

Nov 29, 2019 05:00 pm ET

Medexus Pharmaceuticals Reports Operating and Financial Results for the Second Quarter of Fiscal 2020

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the three- and six-month periods ended September 30, 2019. All dollar...

Nov 25, 2019 09:22 am ET

Medexus Pharmaceuticals Schedules Second Quarter Fiscal 2020 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Monday, December 2, 2019 to discuss the Company’s financial results for the...

Nov 19, 2019 08:30 am ET

Medexus Granted Priority Review Status for Gliolan® by Health Canada

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Canada has granted priority review status for the New Drug Submission (NDS) for Gliolan® (5-aminolevulinic acid hydrochloride)....

Oct 22, 2019 09:00 am ET

Medexus Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it will be presenting at the Dawson James Securities 5th Annual Small Cap Growth Conference being held on October 28-29, 2019 at the Wyndham...

Oct 15, 2019 11:43 am ET

Medexus Announces Changes to Senior Management

Medexus Pharmaceuticals Inc. (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced changes to the Company’s senior management team. Effective immediately, Mr. Sylvain Chrétien will no longer serve as the Company’s President, Canadian...

Sep 19, 2019 08:30 am ET

Medexus Reports Annual Meeting Results

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces voting results from its Annual Meeting of Shareholders held on September 18, 2019 in Toronto, Ontario (the “Meeting”). A total of 5,228,034 Common...

Sep 12, 2019 08:30 am ET

Medexus Reports Health Quality Ontario Recommends Gliolan® for Public Reimbursement

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, has recommended public funding of Gliolan®...

Aug 22, 2019 04:01 pm ET

Medexus Pharmaceuticals Reports Operating and Financial Results for the First Quarter of Fiscal 2020

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the fiscal quarter ended June 30, 2019. All dollar amounts below are in...

Aug 16, 2019 11:00 am ET

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2020 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM Eastern Time on Thursday, August 22, 2019 to discuss the Company’s financial results for the...

Aug 15, 2019 04:05 pm ET

Medexus Announces DTC Eligibility of its Common Shares in the United States

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the Company's common shares traded in the United States, under the symbol PDDPF, are Depository Trust Company (“DTC”) eligible. DTC is...

Jul 08, 2019 04:05 pm ET

Medexus Pharmaceuticals Announces Operating and Financial Results for Fourth Quarter and Full Fiscal Year Ended March 31, 2019

Jun 28, 2019 08:00 am ET

Medexus Pharmaceuticals Schedules Fourth Quarter and Fiscal 2019 Conference Call

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM Eastern Time on Monday, July 8, 2019 to discuss the Company’s financial results for the fourth...

Jun 25, 2019 08:00 am ET

Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North American commercial platform, announces that Adele M. Gulfo has joined the Company's Board of...

May 14, 2019 08:00 am ET

Medexus Pharmaceuticals Announces Normal Course Issuer Bid

Medexus Pharmaceuticals Inc. (the “Company”) (TSXV: MDP, OTCQB: PDDPF) announced today it has submitted to the TSX Venture Exchange (the “Exchange”) a notice of its intention to make a normal course issuer bid (the “Bid”). Provided the Company...

May 07, 2019 12:43 pm ET

Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis in Canada

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose in Canada. Metoject Subcutaneous is a pre-filled syringe of methotrexate with a pre-attached...

Apr 23, 2019 08:00 am ET

Ad blocking detected

Medexus Pharmaceuticals Inc. (V:MDP)

Business Focus: Pharmaceuticals (NEC)